850 related articles for article (PubMed ID: 23532241)
1. Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non-cystic fibrosis bronchiectasis: the BAT randomized controlled trial.
Altenburg J; de Graaff CS; Stienstra Y; Sloos JH; van Haren EH; Koppers RJ; van der Werf TS; Boersma WG
JAMA; 2013 Mar; 309(12):1251-9. PubMed ID: 23532241
[TBL] [Abstract][Full Text] [Related]
2. Effect of long-term, low-dose erythromycin on pulmonary exacerbations among patients with non-cystic fibrosis bronchiectasis: the BLESS randomized controlled trial.
Serisier DJ; Martin ML; McGuckin MA; Lourie R; Chen AC; Brain B; Biga S; Schlebusch S; Dash P; Bowler SD
JAMA; 2013 Mar; 309(12):1260-7. PubMed ID: 23532242
[TBL] [Abstract][Full Text] [Related]
3. Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial.
Wong C; Jayaram L; Karalus N; Eaton T; Tong C; Hockey H; Milne D; Fergusson W; Tuffery C; Sexton P; Storey L; Ashton T
Lancet; 2012 Aug; 380(9842):660-7. PubMed ID: 22901887
[TBL] [Abstract][Full Text] [Related]
4. Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial.
Saiman L; Anstead M; Mayer-Hamblett N; Lands LC; Kloster M; Hocevar-Trnka J; Goss CH; Rose LM; Burns JL; Marshall BC; Ratjen F;
JAMA; 2010 May; 303(17):1707-15. PubMed ID: 20442386
[TBL] [Abstract][Full Text] [Related]
5. Long-term azithromycin for Indigenous children with non-cystic-fibrosis bronchiectasis or chronic suppurative lung disease (Bronchiectasis Intervention Study): a multicentre, double-blind, randomised controlled trial.
Valery PC; Morris PS; Byrnes CA; Grimwood K; Torzillo PJ; Bauert PA; Masters IB; Diaz A; McCallum GB; Mobberley C; Tjhung I; Hare KM; Ware RS; Chang AB
Lancet Respir Med; 2013 Oct; 1(8):610-620. PubMed ID: 24461664
[TBL] [Abstract][Full Text] [Related]
6. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial.
Saiman L; Marshall BC; Mayer-Hamblett N; Burns JL; Quittner AL; Cibene DA; Coquillette S; Fieberg AY; Accurso FJ; Campbell PW;
JAMA; 2003 Oct; 290(13):1749-56. PubMed ID: 14519709
[TBL] [Abstract][Full Text] [Related]
7. Macrolide antibiotics for bronchiectasis.
Kelly C; Chalmers JD; Crossingham I; Relph N; Felix LM; Evans DJ; Milan SJ; Spencer S
Cochrane Database Syst Rev; 2018 Mar; 3(3):CD012406. PubMed ID: 29543980
[TBL] [Abstract][Full Text] [Related]
8. The effect of long-term macrolide treatment on respiratory microbiota composition in non-cystic fibrosis bronchiectasis: an analysis from the randomised, double-blind, placebo-controlled BLESS trial.
Rogers GB; Bruce KD; Martin ML; Burr LD; Serisier DJ
Lancet Respir Med; 2014 Dec; 2(12):988-96. PubMed ID: 25458200
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of oral amoxicillin-clavulanate or azithromycin for non-severe respiratory exacerbations in children with bronchiectasis (BEST-1): a multicentre, three-arm, double-blind, randomised placebo-controlled trial.
Goyal V; Grimwood K; Ware RS; Byrnes CA; Morris PS; Masters IB; McCallum GB; Binks MJ; Smith-Vaughan H; O'Grady KF; Champion A; Buntain HM; Schultz A; Chatfield M; Torzillo PJ; Chang AB
Lancet Respir Med; 2019 Sep; 7(9):791-801. PubMed ID: 31427252
[TBL] [Abstract][Full Text] [Related]
10. Amoxicillin-clavulanate versus azithromycin for respiratory exacerbations in children with bronchiectasis (BEST-2): a multicentre, double-blind, non-inferiority, randomised controlled trial.
Goyal V; Grimwood K; Byrnes CA; Morris PS; Masters IB; Ware RS; McCallum GB; Binks MJ; Marchant JM; van Asperen P; O'Grady KF; Champion A; Buntain HM; Petsky H; Torzillo PJ; Chang AB
Lancet; 2018 Oct; 392(10154):1197-1206. PubMed ID: 30241722
[TBL] [Abstract][Full Text] [Related]
11. Azithromycin maintenance treatment in patients with frequent exacerbations of chronic obstructive pulmonary disease (COLUMBUS): a randomised, double-blind, placebo-controlled trial.
Uzun S; Djamin RS; Kluytmans JA; Mulder PG; van't Veer NE; Ermens AA; Pelle AJ; Hoogsteden HC; Aerts JG; van der Eerden MM
Lancet Respir Med; 2014 May; 2(5):361-8. PubMed ID: 24746000
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of azithromycin maintenance therapy in primary ciliary dyskinesia (BESTCILIA): a multicentre, double-blind, randomised, placebo-controlled phase 3 trial.
Kobbernagel HE; Buchvald FF; Haarman EG; Casaulta C; Collins SA; Hogg C; Kuehni CE; Lucas JS; Moser CE; Quittner AL; Raidt J; Rosthøj S; Sørensen AL; Thomsen K; Werner C; Omran H; Nielsen KG
Lancet Respir Med; 2020 May; 8(5):493-505. PubMed ID: 32380069
[TBL] [Abstract][Full Text] [Related]
13. Effects of long-term azithromycin therapy on airway oxidative stress markers in non-cystic fibrosis bronchiectasis.
Diego AD; Milara J; Martinez-Moragón E; Palop M; León M; Cortijo J
Respirology; 2013 Oct; 18(7):1056-62. PubMed ID: 23714268
[TBL] [Abstract][Full Text] [Related]
14. Effect of Once-Weekly Azithromycin vs Placebo in Children With HIV-Associated Chronic Lung Disease: The BREATHE Randomized Clinical Trial.
Ferrand RA; McHugh G; Rehman AM; Mujuru H; Simms V; Majonga ED; Nicol MP; Flaegstad T; Gutteberg TJ; Gonzalez-Martinez C; Corbett EL; Rowland-Jones SL; Kranzer K; Weiss HA; Odland JO;
JAMA Netw Open; 2020 Dec; 3(12):e2028484. PubMed ID: 33331916
[TBL] [Abstract][Full Text] [Related]
15. Prolonged treatment with macrolides in adult patients with non-cystic fibrosis bronchiectasis: meta-analysis of randomized controlled trials.
Zhuo GY; He Q; Xiang-Lian L; Ya-Nan Y; Si-Te F
Pulm Pharmacol Ther; 2014 Oct; 29(1):80-8. PubMed ID: 24594263
[TBL] [Abstract][Full Text] [Related]
16. Azithromycin for Indigenous children with bronchiectasis: study protocol for a multi-centre randomized controlled trial.
Valery PC; Morris PS; Grimwood K; Torzillo PJ; Byrnes CA; Masters IB; Bauert PA; McCallum GB; Mobberly C; Chang AB
BMC Pediatr; 2012 Aug; 12():122. PubMed ID: 22891748
[TBL] [Abstract][Full Text] [Related]
17. Bronchiectasis exacerbation study on azithromycin and amoxycillin-clavulanate for respiratory exacerbations in children (BEST-2): study protocol for a randomized controlled trial.
Chang AB; Grimwood K; Wilson AC; van Asperen PP; Byrnes CA; O'Grady KA; Sloots TP; Robertson CF; Torzillo PJ; McCallum GB; Masters IB; Buntain HM; Mackay IM; Ungerer J; Tuppin J; Morris PS
Trials; 2013 Feb; 14():53. PubMed ID: 23421781
[TBL] [Abstract][Full Text] [Related]
18. Study protocol, rationale and recruitment in a European multi-centre randomized controlled trial to determine the efficacy and safety of azithromycin maintenance therapy for 6 months in primary ciliary dyskinesia.
Kobbernagel HE; Buchvald FF; Haarman EG; Casaulta C; Collins SA; Hogg C; Kuehni CE; Lucas JS; Omran H; Quittner AL; Werner C; Nielsen KG
BMC Pulm Med; 2016 Jul; 16(1):104. PubMed ID: 27450411
[TBL] [Abstract][Full Text] [Related]
19. Inhaled liposomal ciprofloxacin in patients with non-cystic fibrosis bronchiectasis and chronic lung infection with Pseudomonas aeruginosa (ORBIT-3 and ORBIT-4): two phase 3, randomised controlled trials.
Haworth CS; Bilton D; Chalmers JD; Davis AM; Froehlich J; Gonda I; Thompson B; Wanner A; O'Donnell AE
Lancet Respir Med; 2019 Mar; 7(3):213-226. PubMed ID: 30658914
[TBL] [Abstract][Full Text] [Related]
20. The effect of azithromycin on structural lung disease in infants with cystic fibrosis (COMBAT CF): a phase 3, randomised, double-blind, placebo-controlled clinical trial.
Stick SM; Foti A; Ware RS; Tiddens HAWM; Clements BS; Armstrong DS; Selvadurai H; Tai A; Cooper PJ; Byrnes CA; Belessis Y; Wainwright C; Jaffe A; Robinson P; Saiman L; Sly PD;
Lancet Respir Med; 2022 Aug; 10(8):776-784. PubMed ID: 35662406
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
